Cost of treating chronic hepatitis B: Comparison of current treatment guidelines

Robotin, Mónica; Patton, Yumi; Kansil, Melanie Q; Penman, Andrew; George, Jacob

doi:10.3748/wjg.v18.i42.6106

Cited by 8 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Gastroenterology Society of Australia recommends that CHB patients with HBV DNA levels > 2000 IU/mL receive treatment regardless of age due to the high risk for HBV-related HCC [25]. Chen CJ et al reported that serum HBV DNA level ≥10,000 copies/mL is a major risk factor for hepatocellular carcinoma irrespective of HBeAg status, ALT level and the presence of cirrhosis [26].…”

Section: Resultsmentioning

confidence: 99%

Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B

Koyuncuer¹

2014

SJCM

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is still a significant healthcare problem all over the world. Between January 2009 and May 2014, a total of 96 patients with chronic hepatitis B (CHB) were enrolled in study. A total of 96 CHB cases were examined. The mean total liver histological activity indices for grade and stage were 6.01±2.46, and 1.6±0.99 and the mean ALT and AST levels were 32.6 ±21.0 IU/L and 25.6 ±11.2 IU/L, respectively. The mean HBV DNA level was 8.9 x106±3.3106 IU/mL. Forty (41.7%) patients had HBV DNA <20 IU/Ml (undetectable) and 14 (14.6%) patients had HBV DNA levels between 21 and 2000 IU/mL. Of the total 96 patients, 100% were HBsAg positive, 88 (91.7%) were HBeAg negative and 8 (8.3%) were HBeAg positive. A significant correlation was found between the HBeAg serostatus, HBV DNA level and the histological activity index necroinflammatory total scores (P= 0.034 and 0.000). We found no correlation between the fibrosis score and HBeAg status (P= 0.451). However, a statistically significant difference was found between HBV DNA levels and stage of fibrosis (P= 0.048). A significant relationship was found between the HBeAg status, HBV DNA level and ALT and AST levels (P= 0.000, 0.000, 0.032, 0.024). The HBeAg status of CHB patients should not affect the treatment response or need for long-term follow-up visits with repeat ALT and HBV DNA levels. However, chronic hepatitis patients who are negative for HBeAg may need different short-term follow-up.

show abstract

Section: Resultsmentioning

confidence: 99%

Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B

Koyuncuer¹

2014

SJCM

View full text Add to dashboard Cite

show abstract

“…10 The economic modelling showed that the estimated costs attributed to surveillance for chronic hepatitis B (4-30% of the programme's total cost) and HCC screening and surveillance (5-9%) were relatively small. 10 All local general practitioners were invited to free "continuing medical education" seminars on hepatitis B and provided with tailored educational resources. A quarter of the local general practitioners attended at least one seminar in the 18 months following the programme's launch.…”

Section: Local Settingmentioning

confidence: 99%

“…Only 8 to 25% of cases -the exact proportion depending on the guidelines that are followed for treatment initiation -require antiviral treatment. 10 However, in the economic modelling, the cost of antiviral drugs accounted for most (54-76%) of the estimated total cost of the programme. 10 The economic modelling showed that the estimated costs attributed to surveillance for chronic hepatitis B (4-30% of the programme's total cost) and HCC screening and surveillance (5-9%) were relatively small.…”

Section: Local Settingmentioning

confidence: 99%

“…10 However, in the economic modelling, the cost of antiviral drugs accounted for most (54-76%) of the estimated total cost of the programme. 10 The economic modelling showed that the estimated costs attributed to surveillance for chronic hepatitis B (4-30% of the programme's total cost) and HCC screening and surveillance (5-9%) were relatively small. 10 All local general practitioners were invited to free "continuing medical education" seminars on hepatitis B and provided with tailored educational resources.…”

Section: Local Settingmentioning

confidence: 99%

See 1 more Smart Citation

Community-based prevention of hepatitis-B-related liver cancer: Australian insights

Robotin

Kansil²,

Porwal

et al. 2014

Bull. World Health Organ.

View full text Add to dashboard Cite

“…Patienten mit Besuchen bei Fachärzten für Infektiologie oder Gastroenterologie erhielten deutlich mehr diagnostische Leistungen und vor allem häufiger eine antivirale Therapie [25]. In einem gesundheitsökonomischen Modell für die Therapie von Hepatitis B-infizierten Patienten errechneten Robotin und Kollegen für Einwanderer aus asiatischen Ländern nach Australien die Kosten für verschiedene leitlinienbezogene Versorgungsansätze (australisches Versorgungsprogramm, AASLD, AESL, APASL) über einen Zeitraum von 50 Jahren [26]. Wegen der unterschiedlichen leitliniengerechten Einschlusskriterien differierten die Kosten zwischen 6344 AUD bei Anwendung der AASLD-Guidelines und 14 039 AUD bei EASL-Guidelines.…”

Section: Diskussionunclassified

HBV-Infektionen in Deutschland – Versorgungskosten in einem Real-life-Setting

et al. 2017

View full text Add to dashboard Cite

An estimated 500 000 people are infected with hepatitis B in Germany, inducing an enormous burden on infected patients and the health care system. The aim of our study was to estimate the real-life costs of treating hepatitis B and to analyze sociodemographic factors. We conducted a retrospective, non-interventional, single-center study from 07/2009 to 12/2012. Information on health care delivery was extracted from patient records. Besides that, a questionnaire survey regarding sociodemographic parameters and quality of life of HBV-infected patients was performed. A total of 117 patients were included in our study and grouped in six different disease stages. The response rate of our survey was 80 %. We determined annual total costs of € 3509. The different groups altered between € 221 and € 5618. The main costs (80 %) were caused by the antiviral therapy. Costs of co-medication and hospitalizations were of minor importance. Laboratory costs were primarily caused by determination of virological parameters. Route of transmission of HBV-infection was unknown in 2/3 of all cases. Restrictions in quality of life due to the HBV-infection were reported by 60 % of the patients. Patients receiving interferon treatment reported highest restrictions. In an extrapolation, we estimated total annual hepatitis B treatment costs of 430 million € in Germany. This is the first study estimating real-life treatment costs of hepatitis B infections in Germany. Further research should follow in the context of newly introduced generic antivirals.

show abstract

Cost of treating chronic hepatitis B: Comparison of current treatment guidelines

Abstract: The significant cost variations in CHB screening and treatment using different guidelines are relevant for clinicians and policy makers involved in designing population-based disease control programs.

Cited by 8 publications

References 23 publications

Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B

Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B

Community-based prevention of hepatitis-B-related liver cancer: Australian insights

HBV-Infektionen in Deutschland – Versorgungskosten in einem Real-life-Setting

Contact Info

Product

Resources

About